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Abstract
Environment-driven metabolic reprogramming is a persistent feature throughout the life cycle of T cells and is
essential for their normal development and functioning. Consequently, abnormal metabolic adaptation
underpins a number of human diseases, including cancer. Although the great metabolic adaptation potential
helps T cells to survive nutrient-restricted regions in the periphery and fulfill their duty in immune
surveillance and other functions, it also helps T cell derived tumor cells to survive the nutrient-deprived
tumor microenvironment, thus making them more resilient and difficult to combat. It has long been shown
that cancer cells exhibit a metabolic shift from oxidative phosphorylation to aerobic glycolysis, a phenomenon
known as the Warburg effect. A similar metabolic shift is also observed in activated T cells, suggesting a
common mechanism between immune activation and tumorigenesis. However, this mechanism remains to be
elucidated. The lymphoid-specific NF-κB family transcription factor c-Rel is a key regulator of B- and T-cell
activation and immune response, and has been implicated in a number of hematopoietic cancers. To
investigate the function and regulation of c-Rel in human T cells, we generated c-Rel knockout human T cell
line Jurkat cells using the CRISPR/Cas9 system and analyzed the resulting phenotype. Our results revealed
that c-Rel is a key metabolic regulator that facilitates T cell growth and proliferation by regulating energy
metabolism to promote glycolysis and mitochondrial respiration. Disruption of c-Rel in Jurkat cells leads to
dramatic reduction in cell growth and broad defects in both glycolysis and mitochondrial respiration. These
metabolic defects are also observed in primary T cells isolated from c-Rel knockout mice, demonstrating c-
Rel’s critical role in regulating T cell metabolism across species. Moreover, c-Rel knockout (KO) cells failed to
adapt to nutrient-limited conditions and lost their proliferative capacity. Mechanistically, c-Rel is upregulated
in response to nutrient stress and drives the expression of c-Myc – a potentiator of many genes in the
glycolytic and mitochondrial respiratory pathway. Overexpression of c-Myc in c-Rel KO cells compensated for
the loss of c-Myc induction under nutrient stress, and reversed the proliferative and metabolic defects. These
results establish that c-Rel is a key stress responder and metabolic regulator that maintains cell growth and
survival under nutrient stress and promotes the Warburg effect. Thus, strategies targeting c-Rel may provide
an effective way to suppress cancer metabolism.
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Biology
First Advisor
Youhai H. Chen
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2450
Keywords
c-Rel, glycolysis, mitochondrial respiration, NF-kB, nutrient stress, T cell metabolism
Subject Categories
Allergy and Immunology | Immunology and Infectious Disease | Medical Immunology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2450
THE C-REL TRANSCRIPTION FACTOR CONTROLS METABOLISM AND 
PROLIFERATION OF HUMAN T CELLS 
George S. Luo 
A DISSERTATION 
in 
Biology 
Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
2017 
Supervisor of Dissertation 
____________________________ 
Youhai H. Chen, M.D., Ph.D. 
Professor of Pathology and Laboratory Medicine 
Graduate Group Chairperson 
____________________________ 
Michael Lampson, Ph.D. 
Associate Professor of Biology 
Dissertation Committee  
Wei Guo, Ph.D., Professor of Biology (Chair) 
Erfei Bi, Ph.D., Professor of Cell and Developmental Biology 
Wayne W. Hancock, M.D., Ph.D., Professor of Pathology and Laboratory Medicine 
Robert P. Ricciardi, Ph.D., Professor of Microbiology 
Andrew D. Wells, Ph.D., Associate Professor of Pathology and Laboratory Medicine 
THE C-REL TRANSCRIPTION FACTOR CONTROLS METABOLISM AND 
PROLIFERATION OF HUMAN T CELLS 
COPYRIGHT 
2017 
George S. Luo 
This work is licensed under the  
Creative Commons Attribution- 
NonCommercial-ShareAlike 3.0 
License 
To view a copy of this license, visit 
https://creativecommons.org/licenses/by-nc-sa/3.0/us/ 
iii 
 
ACKNOWLEDGMENTS 
I want to thank my mentor, Dr. Youhai Chen for providing me the wonderful 
opportunity to be part of his lab.  His generous support and wise advice, combined 
with his programmatic approach to scientific challenges, demonstrated all the best 
qualities a scientist can have.  In our conversations, he often presses me on the fine 
points of experimental design.  Dr. Chen has inspired my desire to become a rigorous, 
methodologically sophisticated scholar, to which I am forever grateful.  In addition, 
the warm and supportive environment in Dr. Chen’s lab mirrored the happy years I 
spent at Caltech as an undergraduate, and his unwavering support and 
encouragement to my future endeavors helped me to embrace my aspirations and 
follow in his footsteps with great confidence. 
I also want to thank my mentors at Caltech, Dr. David Baltimore and late Dr. 
Seymour Benzer.  They both have encouraged me to set ambitious goals and 
stimulated my appreciation that there is more than one pathway.  Dr. Baltimore 
modeled for me scientific courage, and his advocacy of science as an agent of social 
change has also affected me deeply.  In Dr. Benzer, I have found a mentor with an 
unsurpassed zeal for science and scientific discovery.  He is a great source of 
inspiration for me as I view him as someone motivated by genuine intellectual 
curiosity. 
I want to thank Dr. Xinyuan Li for his intellectual and experimental 
contribution to this work.  His expertise in metabolic analysis and data mining, 
iv 
 
combined with rigorous yet expeditious experimental execution, played a key part in 
this project.  I also want to thank Dr. Honghong Sun, who helped me on numerous 
projects and experiments throughout my time in the lab. 
Finally, I want to thank members of my thesis committee: Drs. Wei Guo, Erfei 
Bi, Wayne Hancock, Robert Ricciardi, and Andrew Wells, for devoting their valuable 
time to provide critical opinions and guidance on my thesis work.  Their advice and 
suggestions helped to address several key issues along the way. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ABSTRACT 
 
THE C-REL TRANSCRIPTION FACTOR CONTROLS METABOLISM AND 
PROLIFERATION OF HUMAN T CELLS 
George S. Luo 
Youhai H. Chen 
Environment-driven metabolic reprogramming is a persistent feature 
throughout the life cycle of T cells and is essential for their normal development and 
functioning.  Consequently, abnormal metabolic adaptation underpins a number of 
human diseases, including cancer.  Although the great metabolic adaptation potential 
helps T cells to survive nutrient-restricted regions in the periphery and fulfill their 
duty in immune surveillance and other functions, it also helps T cell derived tumor 
cells to survive the nutrient-deprived tumor microenvironment, thus making them 
more resilient and difficult to combat.  It has long been shown that cancer cells exhibit 
a metabolic shift from oxidative phosphorylation to aerobic glycolysis, a phenomenon 
known as the Warburg effect.  A similar metabolic shift is also observed in activated 
T cells, suggesting a common mechanism between immune activation and 
tumorigenesis.  However, this mechanism remains to be elucidated.  The lymphoid-
specific NF-κB family transcription factor c-Rel is a key regulator of B- and T-cell 
activation and immune response, and has been implicated in a number of 
hematopoietic cancers.  To investigate the function and regulation of c-Rel in human 
T cells, we generated c-Rel knockout human T cell line Jurkat cells using the 
CRISPR/Cas9 system and analyzed the resulting phenotype.  Our results revealed that 
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c-Rel is a key metabolic regulator that facilitates T cell growth and proliferation by 
regulating energy metabolism to promote glycolysis and mitochondrial respiration.  
Disruption of c-Rel in Jurkat cells leads to dramatic reduction in cell growth and broad 
defects in both glycolysis and mitochondrial respiration.  These metabolic defects are 
also observed in primary T cells isolated from c-Rel knockout mice, demonstrating c-
Rel’s critical role in regulating T cell metabolism across species.  Moreover, c-Rel 
knockout (KO) cells failed to adapt to nutrient-limited conditions and lost their 
proliferative capacity.  Mechanistically, c-Rel is upregulated in response to nutrient 
stress and drives the expression of c-Myc – a potentiator of many genes in the 
glycolytic and mitochondrial respiratory pathway.  Overexpression of c-Myc in c-Rel 
KO cells compensated for the loss of c-Myc induction under nutrient stress, and 
reversed the proliferative and metabolic defects.  These results establish that c-Rel is 
a key stress responder and metabolic regulator that maintains cell growth and 
survival under nutrient stress and promotes the Warburg effect.  Thus, strategies 
targeting c-Rel may provide an effective way to suppress cancer metabolism. 
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CHAPTER 1: Introduction 
 
Cellular energy metabolism in T cells 
The human body is composed of plethora of cell types that require varying 
levels of energy supply to support their basic and functional activity.  The versatility 
of many cell types in the immune system demands that they produce higher energy 
to support functions such as migration, antigen presentation, cytokine production 
and phagocytosis.  Nevertheless, in all cell types, free energy is mainly presented in 
the form of adenosine 5’-triphosphate (ATP).  ATP is produced most efficiently 
through the process of oxidative phosphorylation (OXPHOS) in the mitochondrial 
respiratory chain (Chaban et al., 2014).  During this process, reduced forms of 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) 
are oxidized to generate a proton gradient, which in turn powers the phosphorylation 
of adenosine 5’-diphosphate (ADP) to produce ATP.  NADH and FADH2 can be derived 
from multiple sources, including glucose, the amino acid glutamine, and free fatty 
acids.  The typical OXPHOS reaction produces approximately 30 molecules of ATP 
from one molecule of glucose via pyruvate intermediate.  As its name implies, 
OXPHOS is strongly dependent on oxygen availability.  In the absence of oxygen, a less 
efficient process, glycolysis, can be used to produce ATP from glucose.  However, 
glycolysis has much lower glucose-to-ATP conversion efficiency, yielding only two 
molecules of ATP from each molecule of glucose.  Despite the lower ATP-per-glucose 
2 
 
yield, glycolysis can produce ATP in greater amount at a faster rate than OXPHOS 
(Voet et al., 2011), making it more suitable for cancer and normal proliferating cells. 
In addition to oxygen availability, the mode of ATP production chosen by cells 
also depends on their functional requirement.  For example, different subsets of T 
cells with distinct functions adapt different energetic and biosynthetic metabolic 
programs.  Conversely, changes in cell metabolism can enhance or suppress immune 
functions at both the cell and system levels (MacIver et al., 2013). 
The activation of naïve CD4+ and CD8+ T cells upon antigen/ T-cell receptor 
(TCR) stimulation leads to differentiation into various types of effector and memory 
cells, which are capable of migrating into affected tissues and secrete effector 
cytokines (Geginat et al., 2013).  Being quiescent and non-proliferating cells, naïve T 
cells generate energy mainly through mitochondria-dependent OXPHOS to support 
basic housekeeping tasks such as vesicle transport, cytoskeleton and membrane 
maintenance, and proteasomal recycling (Guppy et al., 1993).  In contrast, activated 
T cells need a metabolic program that can support the increased energy demands 
associated with rapid cell growth, proliferation, and effector functions such as 
cytotoxicity and cytokine production.  In addition, the activation-induced 
differentiation, clonal expansion and cytokine production requires processing of 
metabolites into building materials to support these activities (Verbist et al., 2012).  
Therefore, even in the presence of sufficient oxygen, activated T cells still use 
glycolysis, i.e., aerobic glycolysis, as their primary mode of energy metabolism (Fox 
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et al., 2005).  Activated T cells also show a substantial increase in glucose uptake 
through the anabolic pentose phosphate pathway, leading to increased synthesis of 
nucleotides, proteins, and lipids (Maciolek et al., 2014).  The conversion of effector T 
cells into quiescent memory T cells is accompanied by yet another metabolic switch 
back to OXPHOS and fatty acid catabolism (Geginat et al., 2001), demonstrating the 
plasticity of T cells in metabolic reprogramming.  In term of CD4 + T helper (Th) cells, 
although Th1, Th2, and Th17 cells all rely on glucose for ATP production, Th17 cells 
have higher rates of glycolysis (Chang et al., 2013).  In contrast to these pro-
inflammatory T helper cells, the anti-inflammatory regulatory T (Treg) cells have 
increased OXPHOS – a key metabolic difference between the reciprocal Th17 and 
Treg cells (Michalek et al., 2011; Shi et al., 2011). 
The metabolic switch from glucose and fatty acid oxidation through the TCA 
cycle to the glycolytic, glutaminolytic, and pentose-phosphate pathways following T 
cell activation has several known regulators.  One of them is the transcription factor 
v-Myc myelocytomatosis viral oncogene homolog (c-Myc).  Upon activation through 
TCR, c-Myc is significantly upregulated at both the mRNA and the protein levels and 
promotes the expression of an assortment of genes that are central to glycolysis and 
glutaminolysis (Wang et al., 2011).  These include the glucose transporter GLUT1, 
hexokinase 2 (HK2), phosphofructokinase (PFKM), enolase 1 (ENO1), lactate 
dehydrogenase A (LDHA), and pyruvate dehydrogenase kinase PDK1 (Kim et al., 2004 
and 2007; Osthus et al., 2000; Shim et al., 1997).  The latter two convert pyruvate to 
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lactate during glycolysis, and block the entry of pyruvate into the TCA cycle, 
respectively. 
Activation through TCR, costimulatory molecules and cytokine receptors also 
leads to upregulation of the phosphatidylinositol 3-kinase (PI3K), Protein kinase B 
(AKT), and mechanistic-mammalian target of rapamycin (mTOR) pathway, which 
plays a crucial role in promoting glucose metabolism and aerobic glycolysis, and 
preventing T cell anergy (Frauwirth et al., 2002; van der Windt et al., 2012).  Activated 
Akt and mTOR complex 1 (mTORC1) promote plasma membrane translocation of 
GLUT1 and inhibit its internalization (Gerriets et al., 2012).  They also promote 
expression of amino acid transporter and activation of glycolytic enzymes to increase 
glucose and glutamine flux (Edinger, 2007; John et al., 2011).  Furthermore, mTOR 
can enhance protein translation by phosphorylating eukaryotic translation initiation 
factor 4E-binding protein 1 (4EBP) (Tandon et al., 2011). 
In contrast to mTOR that promotes anabolic processes to support cell growth, 
the AMP activated protein kinase (AMPK) is a metabolic regulator that senses 
increased ratio of AMP to ATP and upregulates energy-producing catabolic pathways 
to maximize ATP production (Hardie, 2007), while at the same time suppressing ATP 
consumption through inhibition of mTOR.  Immunosuppressive Treg cells show 
increased OXPHOS that corresponds to increased phosphorylation of AMPK 
(Michalek et al., 2011; Cobbold, 2013). 
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Another known metabolic regulator is hypoxia-inducible factor-1 (HIF-1).  
Hypoxia, i.e., abnormally low oxygen concentration (≤1% O2) due to insufficient 
oxygen supply and/or increased oxygen consumption, can occur under a number of 
pathophysiological conditions such as inflammation and tumor growth (Caldwell et 
al., 2001; Gaber et al., 2005).  The functions of immune cells demand that they have 
the ability to travel to these sites, adapt to the local environment and perform their 
intended functions.  Because most T cell functions are highly energy-dependent, they 
need to be able to quickly switch from OXPHOS and aerobic glycolysis to anaerobic 
glycolysis in response to hypoxia (Semenza, 2012).  HIF-1 is a transcription factor 
that serves as an oxygen sensor and an effector of hypoxic response (Semenza, 2007 
and 2014).  Upon hypoxia, the α-subunit HIF-1 is stabilized and enters the nucleus to 
dimerize with the β-subunit, resulting in activation.  The activated HIF-1 then drives 
transcription of a large number of targets, including angiogenic factors such as VEGF, 
chemokine receptor CXCR4, as well as a number of glycolysis-related genes (Schodel 
et al., 2011).  HIF-1 has been shown to promote Treg functions by suppressing T cell 
activation and effector functions, thus providing a link between hypoxia and 
immunosuppression (Ben-Shoshan et al., 2008; Ohta et al., 2011; McNamee et al., 
2013; Bollinger et al., 2014).  However, HIF-1 has also been shown to bias naïve CD4+ 
T-cell differentiation towards the Th17 lineage through upregulation of RORγt and 
downregulation of Foxp3, thereby blocking the generation of Treg cells (Korn et al., 
2009; Dang et al., 2011).  Therefore, HIF-1 provides a good example of how 
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environmental stress drives metabolic change, which in turns alters T cell 
differentiation and function (Ikejiri et al., 2012). 
Metabolic alteration is also implicated in failed immune responses.  For 
example, TCR stimulation with incomplete CD28 co-stimulation leads to failure to 
switch from OXPHOS to glycolysis, causing deficiency in nutrient supply and inability 
to activate, grow, and proliferate (Powell et al., 2010; Du et al., 2012).  This state of 
anergy can be induced by tumors for immune evasion.  Tumor-associated antigen 
presenting cells (APCs) has been shown to alter expression of B7 family membrane 
proteins, thereby disrupting CD28 signaling (Crespo et al., 2013).  In addition, hypoxia 
in the tumor microenvironment can promote immunosuppressive functions of Treg 
cells in a HIF-1–dependent manner (Ohta et al., 2006 and 2012).  Nevertheless, recent 
advances in checkpoint blockade cancer immunotherapy targeting immunoinhibitory 
receptors CTLA4 and PD-1 have demonstrated that T cells are fundamentally capable 
of executing effector functions in the nutrient-deprived tumor microenvironment 
(Pardoll, 2012; Pico de Coaňa et al., 2015). 
 
The Warburg effect 
The switch from oxidative phosphorylation to aerobic glycolysis is not unique 
to activated T cells.  Indeed, this phenomenon was first observed nearly a century ago, 
when Otto Warburg discovered that cancer cells shift their energy supply from 
mitochondrial respiration to glycolysis, even in the presence of sufficient oxygen that 
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could support OXPHOS (Warburg, 1956).  The aerobic glycolysis process produces 
ATP and lactate in the cytoplasm without the need of oxygen.  This metabolic 
reprogramming was later termed the Warburg effect and has become a hallmark of 
cancer. 
Despite the long history of research since Warburg’s discovery, the pathways 
governing metabolic reprogramming and the connections between metabolism and 
immunity are now just beginning to be elucidated. 
 
NF-κB transcription factors 
The nuclear factor-κB (NF-κB) family of dimeric transcription factors is 
comprised of five members: NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA/p65, 
RelB, and c-Rel (Hayden et al., 2008; Perkins, 2012).  They are key regulators of innate 
and adaptive immunity but also play pivotal roles in essential cellular processes such 
as cell proliferation, differentiation, stress response, and survival (Grivennikov et al., 
2010; Di Donato et al., 2012).  NF-κB proteins are present in all cell types and are 
normally held in an inactive state through binding to another family of related 
proteins named inhibitors of NF-κB (IκBs).  Similar to IκBs, p105 and p100 also 
possess a series of ankyrin repeats that allow them to serve as inhibitors of other NF-
κB member proteins.  NF-κB proteins are activated by a variety of signals, including 
cellular stress, DNA damage, immune receptor activation, bacterial and viral 
products, and inflammatory cytokines (Perkins, 2007).  These signals lead to 
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activation of the IκB kinases (IKKs), which in turn phosphorylate IκB proteins bound 
to NF-κB dimers, causing them to fall off and are degraded through the ubiquitin 
pathway, and result in the release of active NF-κB dimers.  Activated NF-κB dimers 
then enter the nucleus and activate the expression of their target genes (Perkins, 
2012).  NF-κB activity is tightly controlled through a number of negative feedback 
loops such as synthesis of IκB proteins.  This limits the time and extent of NF-κB 
responses such as inflammation.  Consequently, aberrant NF-κB activation and 
inactivation can cause or contribute to many diseases (Karin, 2009; Bradford et al., 
2014).  A number of inflammatory diseases are driven by aberrant expression of 
inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin 6 (IL-6), 
which are both under the transcriptional control of NF-κB.  Due to the association 
between inflammation and cancer, NF-κB can also contribute to the development of 
inflammation-associated cancers (Karin, 2009).  In most cases, abnormal NF-κB 
activity is driven either by pathological microenvironment, or by mutations or 
dysregulation of upstream regulators such as the Ras family of proto-oncogenes 
(Bradford et al., 2014).  The target genes of NF-κB transcription factors include many 
regulators of cancer-related cellular processes, such as proliferation, apoptosis, 
angiogenesis and metastasis.  Therefore, NF-κB activity can directly or indirectly 
contribute to many aspects of cancer. 
Several recent studies have demonstrated NF-κB’s significant involvement in 
metabolic diseases such as type 2 diabetes, and atherosclerosis (Baker et al., 2011; 
Solinas et al., 2010).  This involvement reflects the close integration of evolutionarily 
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conserved immune and metabolic pathways.  From the species perspective, the 
abilities to endure nutrient stress and to fight against pathogens are both 
fundamental requirements for survival (Hotamisligil et al., 2008).  In addition, 
mounting an effective immune response requires significant energy investment.  
Therefore, a close coordination between immune response and metabolic modulation 
is essential in both processes (Hotamisligil et al., 2008).  This coordination is partly 
achieved through integration of nutrient- and pathogen-sensing machineries 
(Medzhitov, 2008; Barton, 2008).  For example, the pattern-recognition receptors 
Toll-like receptors (TLRs) TLR2 and TLR4 can sense both lipopolysaccharides (LPS) 
in bacterial walls as well as fatty acids (Kawai et al., 2007).  Conversely, metabolic 
hormones such as leptin and nutrient sensors such as peroxisome proliferator 
activated receptor (PPAR) also regulate immune functions (Lago et al., 2008; 
Hotamisligil, 2010).  Thus, it is not surprising that pathogens can interfere with 
metabolic regulation and that nutrients can induce immune responses.  The NF-κB 
signaling pathway serves as a key connection between inflammation and metabolism 
(Baker et al., 2011).  As an example, a number of metabolic stress sensors and 
cytokine receptors including tumor necrosis factor (TNF) receptors, interleukin-1 
(IL-1) receptor, and TLRs converge on IKKβ, leading to NF-κB activation and 
expression of inflammatory genes, such as TNFα, IL-1β, and IL-6 (Solinas et al., 2010).  
Recent evidence also indicates that high-calorie diet can induce ER stress, causing NF-
κB activation and inflammatory response (Cai et al., 2005; Zhang et al., 2008; Chiang 
et al., 2009). 
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NF-κB has been known to integrate many signals that drive cell activation and 
proliferation during immune response and oncogenesis (Di Donato et al., 2012; 
Perkins, 2012; Kawauchi et al., 2008; Johnson et al., 2011).  However, whether it 
directly regulates the metabolic reprogramming required to support cell division 
during these processes are just beginning to be answered.  Recent reports indicate 
that there is a strong connection between NF-κB and metabolism independent of 
inflammation (Mauro et al., 2011).  The NF-κB family member RelA has been shown 
to control energy metabolism through transcriptional regulation of metabolic genes, 
such as the glucose transporter GLUT3, thereby altering the balance between 
glycolysis and OXPHOS (Kawauchi, 2008).  Because both immune response and tumor 
growth involve rapid cell division, it is not surprising that they both utilize increased 
glucose metabolism to meet the strong bioenergetic and biosynthetic demand.  
Situated at the focal point of signal integration, it makes sense for NF-κB to coordinate 
the interrelated metabolic and immunological processes.  Finally, although the NF-κB 
family is known to play a crucial function in regulating a large number of genes 
involved in immune, developmental and apoptotic processes, the contributions of 
individual member proteins are still elusive. 
 
NF-κB family member c-Rel 
The NF-κB family member c-Rel (encoded by the REL gene in humans) was 
first identified as a homologue of the avian retroviral oncoprotein v-Rel, which causes 
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lymphoma in birds (Gilmore, 2011).  Structurally, c-Rel is similar to RelA and RelB in 
the NF-κB family, containing an N-terminal DNA-binding and dimerization domain, 
termed the Rel homology domain (RHD), and a C-terminal transcriptional activation 
domain (Gilmore, 2006; Martin et al., 2000 and 2001; Starczynowski et al., 2003).  c-
Rel is commonly found as a dimer with p50, RelA, or c-Rel itself, each carrying a 
slightly different DNA-binding specificity (Sanjabi et al., 2005).  c-Rel is generally 
considered a transcriptional activator that promotes a permissive chromatin 
structure at the regulatory region of its target genes (van Essen et al., 2010). 
Unlike other NF-κB family members which are constitutively expressed in 
multiple cell types, c-Rel is expressed primarily in cells of lymphoid and myeloid 
origin, including B and T cells (Brownell et al., 1987; Huguet et al., 1998; Kontgen et 
al., 1995).  In mouse, c-Rel has been shown to regulate the expression of many 
proinflammatory genes such as Il2, Tnf, Ifng, Il1b and Il6 (Pahl, 1999; Natoli et al., 
2005; Carmody et al., 2007).  c-Rel knockout mice show several immunological 
defects, including reduced mature B- and T-cell proliferation and activation in 
response to mitogenic stimuli and abnormal germinal center formation (Gilmore and 
Gerondakis, 2011).  c-Rel also plays an important role in a number of autoimmune 
diseases such as inflammatory bowel disease and rheumatoid arthritis (Wang et al., 
2008).  c-Rel knockout mice are resistant to a number of autoimmune diseases, such 
as experimental autoimmune encephalomyelitis (EAE) and colitis (Campbell et al., 
2000; Hilliard et al., 2002).  c-Rel is also a key player in the development of 
suppressive regulatory T cells and inflammatory Th17 cells through transcriptional 
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regulation of Foxp3 and RORγT, respectively (Carmody et al., 2007; Ruan et al., 2009 
and 2010).  In addition, T cells isolated from c-Rel knockout mice fail to proliferate 
upon anti-CD3 or phorbol myristate acetate (PMA)/ionomycin stimulation (Liou et 
al., 1999).  However, this phenotype was attributed to a deficiency in interleukin 2 
(IL-2) production insofar as supplementation of exogenous IL-2 rescued the 
proliferation defect. 
 
c-Rel in diseases 
c-Rel has been linked to a number of human diseases through genomic and 
cytogenetic studies.  Polymorphisms at the REL locus are associated with several 
autoimmune diseases, including rheumatoid arthritis (Gregersen et al., 2009; Eyre et 
al., 2010; Varadé et al., 2011), Crohn’s disease (Cho et al., 2011), celiac disease 
(Trynka et al., 2009), psoriasis (Strange et al., 2010), and primary sclerosing 
cholangitis (Janse et al., 2011).  REL gene amplifications and increased c-Rel 
expression have been found in a variety of B and T cell malignancies, such as 
Hodgkin’s lymphoma, diffuse large B-cell lymphoma (DLBCL), and Adult T-cell 
leukemia/lymphoma (ATLL) (Fukuhara et al., 2006; Mader et al., 2007; Staudt et al., 
2007; Courtois et al., 2006; Ramos et al., 2007).  However, in several animal studies, 
c-Rel-/- mice have shown greater susceptibility to cancer models, including colitis-
associated colon adenocarcinoma and H. felis-induced model of gastric cancer 
(Burkitt et al., 2013 and 2015).  Given c-Rel’s importance in modulating immune 
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functions, these studies suggest that in addition to its inflammation-related tumor-
promoting properties, c-Rel can also help to suppress tumorigenesis through its 
proper immune-regulatory role to support immune surveillance.  Nevertheless, 
mechanistically how c-Rel contributes to tumorigenesis as a pathogenic factor 
remains unclear. 
Despite the importance of c-Rel in T cell functions and its implications for diseases, 
the specific role it plays in metabolic regulation has not been identified.  The 
elucidation of c-Rel's role in energy metabolism and its significance in cancer 
development will not only advance our knowledge of how NF-κB functions in cancer, 
but also open new opportunities for identifying better targeting strategies of 
therapeutic intervention.  Finally, because c-Rel is expressed preferentially in cells of 
lymphoid and myeloid lineages, drugs targeting c-Rel could have significantly less 
side effects than drugs targeting the other components or upstream regulators of the 
NF-κB pathway. 
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CHAPTER 2: c-Rel Is a Key Regulator of T Cell Proliferation under 
Nutrient Stress 
 
Introduction 
The NF-κB family member c-Rel was first discovered as a homologue of the 
avian retroviral oncoprotein v-Rel.  It is also the only NF-κB family member that can 
transform primary chicken spleen cells in vitro (Gilmore, 1999 and 2001).  c-Rel is 
also unique in its preferential expression in lymphoid and myeloid cells, and its 
specific roles in B and T cell differentiation and function: c-Rel deficient mice exhibit 
reduced B cell activation, proliferation and survival, as well as defective Th1 response 
and Treg/Th17 development (Rao et al., 2003; Mason et al., 2004; Ruan et al., 2009 
and 2010; Isomura et al., 2009). 
Several pieces of evidence have implicated c-Rel in a number of human 
diseases.  First, genome-wide association studies (GWAS) studies have linked 
polymorphism at the human REL locus to many autoimmune diseases (e.g., 
rheumatoid arthritis, psoriasis and celiac disease) and blood cancers (e.g., diffuse 
large B-cell lymphoma and Hodgkin's lymphoma) (Gilmore and Gerondakis, 2011).  
Second, REL gene amplifications and increased c-Rel expression have been found in a 
variety of B and T cell malignancies, such as Hodgkin’s lymphoma, diffuse large B-cell 
lymphoma (DLBCL), and Adult T-cell leukemia/lymphoma (ATLL) (Hunter et al., 
2016).  And third, c-Rel knockout mice are resistant to models of RA, multiple 
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sclerosis (MS), type I diabetes and colitis (Gilmore and Gerondakis, 2011).  Despite 
these implications, the questions of if and how c-Rel functions as a pathogenic factor 
remain unanswered.  In addition, because most of the current knowledge on c-Rel is 
derived from mouse studies, whether they hold true in human remain to be seen. 
Given the potential involvement of NF-κB in T cell and cancer metabolism as 
described in Chapter 1, we decided to investigate the specific functions of c-Rel in 
human T cells with an emphasis on cancer- and metabolism-related processes. 
In biology, the ideal first step towards understanding the function and 
importance of a protein is to remove its activity by knocking out its encoding gene 
and assess the impact.  The results will lay the foundation for further investigations.  
Although c-Rel knockout mice have been generated for some time, to date there has 
been no report of human based c-Rel knockout cells being created or analyzed.  With 
the recent advent of the CRISPR/Cas9 gene editing system, we decided to take 
advantage of this promising new technology to create the first human-based c-Rel 
knockout cell line.  The first step of creating a knockout cell line is to select a suitable 
cell line as the model system and starting point.  Based on our goal of studying c-Rel 
function in T cells, the ideal cell line should meet several criteria.  First, it should be 
of T cell origin.  Second, it should retain as much T-cell specific phenotype as possible.  
And third, it should have significant c-Rel expression.  The human T cell leukemia line 
Jurkat meets all three criteria and was therefore selected as our model system. 
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Results 
Generating c-Rel knockout (KO) Jurkat cells using the CRISPR/Cas9 system 
To determine the specific functions of c-Rel in human T cells, we generated c-
Rel knockout lines from the Jurkat human leukemia T cells using a CRISPR/Cas9 
system.  This specific system is comprised of two lentiviral-based vectors (Fig. 1A).  
The first vector (pCW-CAS9) carries the Cas9 endonuclease under the control of a Tet-
On tetracycline inducible expression system, as well as a constitutively expressed 
puromycin resistance gene.  The second vector (pLX-sgRNA) carries a single-guide 
RNA (sgRNA) driven by the U6 RNA polymerase III promoter, as well as a blasticidin 
resistance gene.  The main advantage of this two-vector system over most one-vector 
based systems is that the Cas9 endonuclease is expressed only when doxycycline is 
added to the culture medium.  The level of Cas9 will go down following the 
withdrawal of doxycycline from the culture media after gene editing has been 
completed.  This helps to maintain genomic stability of the knockout cells by 
preventing unintended mutations created by excess amount of Cas9 protein.  Our goal 
is to create frame-shift mutations near the N-terminus of the c-Rel coding sequence, 
thereby eliminating the translated c-Rel protein in its entirety.  To achieve this goal, 
we designed eight sgRNA sequences, all targeting sites near the 5’ end of the c-Rel 
coding sequence, and cloned them in to the pLX-sgRNA lentiviral vector.  Five sgRNAs 
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whose target sites are closest to the 5’ end of the c-Rel sequence were made into 
viruses and used to produce c-Rel KO cells (Fig 1B). 
We first transduced the wild-type Jurkat (WT) cells with the pCW-Cas9 vector, 
followed by one week of puromycin selection and one week of expansion.  The 
selected cells were then transduced again with the pLX-sgRNA vector followed by one 
week of blasticidin selection in the presence of doxycycline.  The remaining cells were 
expanded to suitable numbers and analyzed for knockout efficiency using western 
blotting.  The result indicated that two sgRNA sequences (#5 and 6) produced notable 
knockdown effect, while a third sequence (#2) showed weaker effect.  One phenotype 
we noticed immediately was that cells transduced with sgRNA #5 and #6 grew much 
slower than cells transduced with the other sgRNAs.  Because the sgRNA #6 group 
showed the strongest knockdown, we measured its growth rate against control 
groups (Fig. 2B).  The growth curve indeed confirmed our initial observation. 
The cells obtained by the end of blasticidin selection and doxycycline 
treatment are heterogeneous populations of c-Rel KO and non-KO cells.  Because 
there appears to be a difference in growth rate between c-Rel KO and non-KO cells, 
the composition of these populations is unstable.  We therefore proceeded with 
creating homogeneous c-Rel KO lines through clonal selection.  The clonal selection 
gave rise to three c-Rel KO lines from different sgRNA groups and three sgRNA control 
clones (Fig. 3A), which were used in subsequent comparisons. 
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Because the critical dependence of IL-2 induction on c-Rel has been well 
established in mice, we measured IL-2 mRNA induction using quantitative PCR 
(qPCR) for functional confirmation of successful c-Rel knockout.  The results 
confirmed that all three c-Rel KO lines failed to induce IL-2 expression upon 
PMA/ionomycin stimulation, while three control cell lines created through the same 
processes, but with an AAVS1-targeting control sgRNA, strongly expressed IL-2 upon 
stimulation (Fig. 3B). 
The clonal selection process inevitably introduces selection bias in terms of 
growth rate.  That is, non-proliferating or slow-proliferating cells will not come out of 
the selection.  As a result, the growth rate differences observed before clonal selection 
growth were no longer evident when grown under standard culture medium 
containing 10% fetal bovine serum (FBS).  However, upon placing the cells under 
nutrient stress by lowering serum concentration in the culture medium, all three c-
Rel KO lines showed significantly lowered growth and survival rates (Fig. 4 and Fig. 
5A).  We therefore selected 2% FBS concentration as our standard serum starvation 
condition. 
To confirm that this difference is due to c-Rel deletion and not to off-target 
effects of the CRISPR/Cas9 system, we re-expressed c-Rel in the KO cells under the 
control of the human Ubiquitin C (UbC) promoter using a lentiviral vector that also 
co-express GFP under the control of an internal ribosome entry site (IRES) element 
(Fig. 6A) for FACS-based selection (Fig. 6B and C).  Western blotting confirmed 
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successful re-expression of the c-Rel protein, albeit at a higher level than the wt and 
sgRNA control groups.  This ectopic expression of c-Rel rescued approximately 70% 
of the proliferation defect at day 6 (Fig. 7B), suggesting that the proliferation defect 
is indeed mostly attributable to c-Rel ablation. 
 
c-Rel KO cells show impaired glucose and glutamine utilization 
To find out which components in the medium were involved in the 
proliferation defect of the c-Rel KO cells, we removed individual components from 
the standard medium and measured the effects by measuring cell growth.  Glucose 
and glutamine are two major energy sources used by cancer and normal proliferating 
cells.  Using glucose-free base medium with or without the addition of glucose, we 
found that while the supplementation of glucose restored growth of the control cells 
under serum starvation, it had no effect on the c-Rel KO cells (Fig. 8A).  Similarly, the 
addition of glutamine to glutamine-free (but not glucose-free) base medium markedly 
enhanced the growth of control cells, but again had no effect on the c-Rel KO cells (Fig. 
8B).  These results suggest that while normal Jurkat cells can utilize glucose and 
glutamine to support their growth and proliferation, the c-Rel KO cells have lost this 
ability regardless the availability of these nutrient sources. 
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c-Rel is required for c-Myc induction upon PMA/ionomycin stimulation or 
serum starvation 
Given c-Rel’s role as a transcription factor and the defects in glucose and 
glutamine utilization of c-Rel KO cells, we hypothesized that c-Rel facilitates cell 
proliferation by mediating the induction of genes crucial for metabolic 
reprogramming during nutrient stress.  Because PMA/ionomycin stimulation is a 
well-established method to reliably elicit strong c-Rel activation, we decided to use 
this condition to screen for potential c-Rel targets that are also metabolic regulators 
involved in nutrient stress response.  Using a high throughput microarray, we 
analyzed the transcriptome of normal and c-Rel KO Jurkat cells upon PMA/ionomycin 
stimulation.  The results revealed downregulation of many metabolism-related genes 
in the c-Rel KO cells.  We subsequently confirmed a number of these genes under 
serum starvation conditions via qPCR (Fig. 10).  We also looked for potential c-Rel 
targets using previous c-Rel-deficient mouse B cell and macrophage microarray data 
sets, and cross-referenced the results to produce a Venn diagram (Fig. 11).  We found 
that three genes: ACAT2, DHCR24, and c-Myc are common c-Rel targets in all three 
cell types of both human and mouse origin.  Our qPCR confirmation experiments also 
showed that c-Myc mRNA expression is significantly induced in response to 
PMA/ionomycin stimulation, and that this induction is completely abolished in the 
absence of c-Rel (Fig. 12A).  Furthermore, when c-Rel is re-expressed in the c-Rel KO 
cells, c-Myc induction is also restored (Fig. 12B).  These results confirmed that c-Myc 
is indeed a c-Rel target in Jurkat T cells. 
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Next, we examined whether c-Myc is upregulated under serum starvation in a 
c-Rel-dependent manner.  Using Western blots, we found that both c-Rel and c-Myc 
protein expressions are increased in a time-dependent manner under serum 
starvation (Fig. 13A).  Importantly, this c-Myc induction is compromised at both the 
mRNA and the protein levels in c-Rel KO cells (Fig. 13B and Fig. 14A).  Again, this 
defect can be rescued by re-expressing c-Rel in the c-Rel KO cells (Fig. 14B).  Taken 
together, these results confirmed that c-Rel controls the induction of c-Myc 
expression during serum starvation. 
 
The 2kb c-Myc promoter region is sufficient for response to c-Rel activation 
The above results suggest that c-Rel might directly control c-Myc induction 
through transcriptional regulation at the c-Myc promoter.  To evaluate this 
possibility, we cloned a 2kb genomic fragment containing the c-Myc promoter and 
inserted it upstream of a luciferase reporter gene (pGL4.12[luc2CP]).  We then tested 
the responsiveness of this reporter construct to c-Rel activation using control and c-
Rel KO Jurkat cells.   The results showed that the c-Myc promoter conferred significant 
transcriptional activity upon PMA/ionomycin stimulation in the presence of c-Rel.  
However, this activity was significantly reduced by c-Rel knockout (Fig. 15).  These 
data are consistent with our hypothesis that c-Rel activates c-Myc expression through 
transcriptional activation of the c-Myc promoter, which likely contains c-Rel-
mediated DNA regulatory elements. 
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c-Myc reverses the cell growth defect of c-Rel KO cells 
We went on to hypothesize that the c-Rel-dependent c-Myc induction is 
required to drive cell proliferation under nutrient stress.  To test this hypothesis, we 
ectopically overexpressed c-Myc in c-Rel KO Jurkat cells under the control of the 
human Ubiquitin C (UbC) promoter using a lentiviral vector that also co-express GFP 
under the control of an internal ribosome entry site (IRES) element (Fig. 16A) for 
FACS-based selection (Fig. 16B and C).  Western blotting showed that this ectopic 
expression increased c-Myc expression at both the mRNA and the protein levels (Fig. 
17).  More importantly, restoring c-Myc expression also reversed the proliferation 
defect of c-Rel KO cells under serum starvation (Fig. 18).  These results suggested that 
the induction of c-Myc expression under serum starvation plays an important role in 
maintaining cell growth and proliferation. 
 
Discussion 
 Our data not only confirmed that c-Rel is a critical factor for the proliferation 
and survival of Jurkat cells under nutrient stress, but also showed that a significant 
portion of this role involves transcriptional upregulation of the proto-oncogene 
protein c-Myc.  c-Myc is a known contributor to the genesis of many human cancers 
(Pelengaris  et al., 2002; Adhikary and Eilers, 2005) and has been shown to regulate 
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a large number of genes involved in cell growth, proliferation, differentiation, 
apoptosis as well as metabolism (Levens, 2002 and 2003).  Indeed, our microarray 
and qPCR data confirmed a number of metabolism-related genes that are also thought 
to be c-Myc targets.  Examples of these metabolic genes include the glucose 
transporter GLUT1, the mitochondrial transcription factors TFAM and PPARGC1A, as 
well as the lipid biosynthesis enzyme SLC27A2 (Fig. 10).  Having shown that c-Rel 
activation can lead to c-Myc induction (Fig. 12), it would not be surprising that 
prolonged activation of c-Rel under inflammatory or other pathological conditions 
may cause persistent c-Myc upregulation, thus increasing the chance of tumorigenic 
transformation.  Therefore, c-Myc may serve as a downstream effector of c-Rel that 
links altered cellular metabolism to tumorigenesis. 
 Mechanistically, c-Myc has been proposed to function as a universal amplifier 
of already expressed genes in lymphocytes and tumor cells (Nie et al., 2013; Lin et al., 
2012).  Chromatin immunoprecipitation coupled to high-throughput sequencing 
(ChIP-Seq) studies suggest that instead of serving as an on-off switch for a new set of 
genes, c-Myc accumulates in the promoter regions of active genes and enhances the 
level of transcription within the cell's existing gene expression program.   This mode 
of function implies that a pre-established permissive chromatin environment is 
required at c-Myc target promoters.  Interestingly, c-Rel has been shown to drive 
chromatin remodeling and establish a permissive chromatin environment at c-Rel-
target promoters (Rao et al., 2003; van Essen et al, 2010).  Having confirmed that c-
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Myc itself is also a target of c-Rel, it is conceivable that their combined actions could 
form a synergistic mechanism to drive strong induction of their common targets. 
Although the present study clearly establishes the growth-deficiency 
phenotype of c-Rel knockout Jurkat cells under nutrient stress, some important 
questions remain to be answered.  For instance, we still do not know if c-Rel is directly 
involved in the initial steps of oncogenic transformation.  Although we propose that 
c-Rel may contribute to this process through upregulation of c-Myc, this has yet to be 
proven experimentally.  The fact that Jurkat is already a cancer cell line makes it 
unsuitable for answering this question.  Therefore, a different approach needs to be 
taken to fully assess c-Rel’s oncogenic potential.  Another interesting observation is 
that although re-expression of c-Rel in the knockout cells achieved much higher 
protein level as indicated by western blotting, it did not fully restore the growth 
defect of the c-Rel (Fig. 7).  This shows that the level of c-Rel expression and the rate 
of cell growth are not in a simple linear relationship.  The incomplete rescue of cell 
growth rate could be a side-effect of excessive c-Rel protein expression.  Or, it could 
be that proper post-transcriptional regulation, such as alternative splicing into 
multiple isoforms, is required for c-Rel’s normal function.  These possibilities will 
need to be explored to fully explain this phenomenon. 
25 
 
 
 
FIGURE 1. Design of a CRISPR/Cas9 system to create human c-Rel knockout cells 
A two-component lentiviral based CRISPR/Cas9 system is used to sequentially deliver Cas9 
endonuclease and single-guide RNA (sgRNA) into cells. A) sgRNAs are constitutively 
expressed under the control of the U6 promoter, while Cas9 is expressed using a tet-on 
system in a doxycycline-dependent manner. B) Five sgRNA sequences (highlighted) targeting 
N-terminus of the c-Rel protein were selected to generate c-Rel knockout cells. The exact 
locations of sgRNA targets are indicated on the c-Rel cDNA sequence map. 
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FIGURE 2. c-Rel knockout Jurkat cells show reduced cell growth 
A) Western blots of Jurkat cells treated with Cas9 and five different c-Rel-targeting sgRNAs 
and an AAVS1-targeting control sgRNA Notable knockdown effect of c-Rel was observed on 
cells treated with sgRNA #5 and #6.  B) Cell growth of Jurkat cells treated with sgRNA #6 was 
measured against control sgRNA-treated and untreated (WT) Jurkat cells.  Values represent 
mean ± SEM (n=3; **p<0.01; one-way ANOVA). 
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FIGURE 3. c-Rel knockout Jurkat cells fail to express IL-2 upon PMA / ionomycin 
stimulation 
A) Western blots of three c-Rel knockout (KO) Jurkat clones and three sgRNA control clones. 
Complete knockout is observed in all three c-Rel KO clones.  B) Control and c-Rel KO Jurkat 
cells were stimulated with or without PMA and ionomycin for 4 hours, followed by RT-qPCR 
assay for human IL-2. Left: Values represent mean ± SEM of pooled samples of equal amounts 
of RNA from 3 clones (n=3; ***p<0.001; one-way ANOVA).  Right: Values represent mean ± 
SEM of individual clones (n=3; *p<0.05; Student’s t-test). 
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FIGURE 4. c-Rel KO Jurkat cells show severe growth and survival defect under low 
serum concentrations 
A) wt and c-Rel KO Jurkat cells were cultured in medium containing 1% FBS for 5 days.  B) wt 
and c-Rel KO Jurkat cells were cultured in medium containing 2% FBS for 5 days.  C) wt and 
c-Rel KO Jurkat cells were cultured in serum-free medium for 5 days.  Values represent mean 
± SEM of 6 technical replicates of one clone in each group (*p<0.05, **p<0.01, ***p<0.001; 
Student’s t-test). 
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FIGURE 5. c-Rel is required for cell growth under serum starvation 
A) sgRNA control (blue), c-Rel KO (red), and wild-type (green) Jurkat T cells were grown in 
culture media containing 2% FBS. Values represent mean ± SEM of 3 independent clones in 
each group (*p<0.05, **p<0.01; Student’s t-test).  B) c-Rel KO cell groups show increased 
culture media acidity as indicated by phenol red color change after 5 days. 
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FIGURE 6. Rescuing c-Rel expression in c-Rel KO cells using a lentiviral vector 
A) Schematic representation of the c-Rel expression lentiviral vector: Human c-el is 
expressed under the control of the ubiquitin C promoter. GFP is co-expressed after an internal 
ribosome entry site (IRES) element following the c-Rel cDNA sequence.  B)  Flow cytometry 
graph of c-Rel KO cells transduced with control vector.  C) FACS sorting of c-Rel KO cells 
transduced with c-Rel and GFP as a marker. 
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FIGURE 7. Re-expressing c-Rel in c-Rel KO cells rescues their growth defect 
A) Western blots from Jurkat cell clones of wild type (WT), sgRNA control (Ctrl), c-Rel KO, c-
Rel KO transduced with GFP-expressing lentiviral vector, and c-Rel KO transduced with c-Rel 
and GFP co-expressing vector. Each blot represents a single clone.  B) Growth curve of sgRNA 
control cells transduced with GFP (blue), c-Rel KO cells transduced with GFP (red), and c-Rel 
KO cells transduced with c-Rel and GFP (green) under 2% serum concentration.  Values 
represent mean ±  SEM of 3 independent clones in each group (***p<0.001; one-way 
ANOVA). 
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FIGURE 8. c-Rel is required for glucose and glutamine utilization 
A) Growth curve of sgRNA control and c-Rel KO Jurkat cells in culture media with or without 
glucose (glu, 11mM) under 2% serum starvation conditions.  B. Growth curve of sgRNA 
control and c-Rel KO cells in culture media with or without glutamine (gln, 2mM) under 2% 
serum starvation conditions.  For all panels, values represent mean ± SEM of 3 independent 
clones in each group (p values for control cells without glu/gln vs control cells with glu/gln: 
*p<0.05, **p<0.01; one-way ANOVA). 
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FIGURE 9. Microarray analysis showing significant biological processes affected by c-
Rel knockout  
Areas represent number of genes involved in the respective processes and are affected by c-
Rel knockout, as identified through gene ontology functional annotation clustering analysis 
based on microarray results. 
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FIGURE 10. c-Rel knockout leads to downregulation of a number of metabolism related 
genes 
Control and c-Rel KO Jurkat cells were cultured in standard culture media and stimulated 
with PMA and ionomycin for 4 hours, followed by RT-qPCR analyses of respective genes.  For 
all panels, values represent mean ± SEM of pooled samples of equal amounts of RNA from 3 
clones (n=3; *p<0.05, **p<0.01, ***p<0.001; Student’s t-test). 
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FIGURE 11. c-Myc is identified as a c-Rel target through microarray analyses. 
Venn Diagram of 3 microarrays comparing c-Rel KO with control in human Jurkat T cells 
stimulated with TCR agonist PMA and ionomycin, mouse macrophages stimulated with 
lipopolysaccharide (LPS), and mouse B cells stimulated with BCR agonist CD40 and IgM. 
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FIGURE 12. c-Rel is required for c-Myc induction under PMA/ionomycin stimulation  
A) sgRNA control and c-Rel KO Jurkat cells were cultured in standard culture media and 
treated with or without PMA/ionomycin stimulation followed by RT-qPCR quantification of 
c-Myc mRNA.  Values represent mean ± SEM of pooled samples of equal amounts of RNA from 
3 clones (n=3; ***p<0.001; one-way ANOVA).  B) c-Rel KO cells transduced with GFP and c-
Rel KO cells transduced with c-Rel and GFP were cultured in standard culture media and 
stimulated with PMA/ionomycin for 4 hours, followed by RT-qPCR quantification of IL-2 
(left) and c-Myc mRNA (right).  Values represent mean ± SEM of individual clones (n=3; 
***p<0.001; Student’s t-test). 
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FIGURE 13. c-Rel knockout leads to deficiency in c-Myc induction under serum 
starvation  
A) sgRNA control and c-Rel KO Jurkat cells were starved under 2% FBS for the indicated times 
followed by  Western blotting for c-Rel and c-Myc. B) sgRNA control and  c-Rel KO Jurkat cells 
were serum starved for 2 days followed by RT-qPCR quantification of c-Myc mRNA.  Data 
were normalized with GAPDH.  Values represent mean ± SEM of individual clones (n=3; 
*p<0.05; Student’s t-test). 
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FIGURE 14. Re-expressing c-Rel in c-Rel KO cells restores c-Myc induction under serum 
starvation 
A) wild-type (WT), sgRNA control (Ctrl), and c-Rel KO Jurkat cell clones were serum starved 
for 2 days followed by Western blotting.  B) Clones of sgRNA control cells transduced with 
GFP, c-Rel KO cells transduced with GFP, and c-Rel KO cells transduced with c-Rel and GFP 
were serum starved for 2 days followed by Western blotting for c-Rel and c-Myc. 
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FIGURE 15. c-Rel drives c-Myc promoter activity 
A) Schematic representation of the c-Myc promoter reporter plasmid: a 2kb human c-Myc is 
inserted upstream of the luciferase reporter gene luc2CP.  B)  Control and c-Rel KO Jurkat 
cells were transfected with a luciferase reporter plasmid containing either no promoter or a 
2kb human c-Myc promoter, and stimulated overnight with PMA and ionomycin followed by 
luciferase assay.  Values represent mean ± SEM (n=3; p values for c-Myc reporter signal in 
WT vs in REL KO: ***p<0.001; one-way ANOVA). 
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FIGURE 16. Rescue of c-Myc deficiency through expression of c-Myc 
A) Schematic representation of the c-Myc expression lentiviral vector: Human c-el is 
expressed under the control of the ubiquitin C promoter. GFP is co-expressed after an internal 
ribosome entry site (IRES) element following the c-Rel cDNA sequence.  B)  FACS sorting of 
c-Rel KO cells transduced with GFP only.  C) FACS sorting of c-Rel KO cells transduced with 
both c-Myc and GFP. 
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FIGURE 17. c-Myc expression compensates c-Myc induction failure in c-Rel KO cells 
A) Western blots of c-Rel KO cells transduced with GFP, c-Rel KO cells transduced with c-Myc 
and GFP, and wild-type Jurkat cells that were cultured in standard media containing 10% FBS.  
Three independent clones in each group are shown.  B) sgRNA control cells transduced with 
GFP, c-Rel KO cells transduced with GFP, and c-Rel KO cells transduced with c-Myc and GFP 
were starved under 2% FBS for 2 days followed by Western blotting.  Three independent 
clones in each group are shown.  C) The indicated cells were starved under 2% FBS for 2 days 
followed by RT-qPCR quantification of c-Myc.  Data were normalized by GAPDH.  Values 
represent mean ± SEM of pooled samples of equal amounts of RNA from 3 clones (n=3; 
***p<0.001; one-way ANOVA). 
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FIGURE 18. c-Myc rescues growth defect of c-Rel KO cells under serum starvation 
Two independent measurements of growth curve of sgRNA control, c-Rel KO, and c-Rel KO 
cells transduced with c-Myc under 2% serum starvation.  Values represent mean ± SEM of 3 
independent clones in each group (***Control vs KO, p<0.001; ##KO+MYC vs KO, p<0.01; 
###KO+MYC vs KO, p<0.001. one-way ANOVA). 
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CHAPTER 3: c-Rel Regulates T Cell Metabolism by Promoting Glycolysis 
and Mitochondrial Respiration 
 
Introduction 
Having confirmed that c-Rel is essential for maintaining cell under serum 
starvation, and that it controls c-Myc induction under the same condition, we want 
to further determine how much does the latter contribute to the former.  Given that 
c-Myc is a known metabolic regulator (Wise et al., 2008; Gaber et al., 2015; Miller et 
al., 2012), it is natural to ask whether c-Rel regulates cell growth through metabolic 
modulation, and if so, does it modulate energy metabolism entirely through driving 
c-Myc induction?  Another question is that because Jurkat is a transformed cancer 
cell line, can the knowledge we learn from Jurkat cells be applied to normal primary 
T cells?  To answer these questions, we decided to perform detailed metabolic 
profiling of the c-Rel KO and the control cells.  Since glycolysis and mitochondrial 
respiration are the two major sources of energy production used by cancer and 
normal cells, we put our emphasis on these two processes.  We started by 
measuring glucose consumption in the culture as a pilot experiment, followed by 
detailed quantification of metabolic parameters of glycolysis and mitochondrial 
respiration using a Seahorse XF extracellular flux analyzer.  Furthermore, we also 
isolated primary mouse CD4+ T cells from c-Rel KO and wild type mice, and 
measured their metabolic parameters using the Seahorse assay. 
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Results 
c-Rel KO cells show reduced glucose consumption 
We started by measuring the glucose consumption of sgRNA control cells, c-
Rel KO cells, and c-Rel KO cells transduced with c-Myc expression vector.  The result 
showed that the c-Rel KO cells consume less glucose than the sgRNA control cells, 
and that ectopic c-Myc overexpression can partially reverse this effect (Fig. 19).  It is 
worth noting that this difference is not merely the results of different cell numbers, 
since this difference is already evident on day two, when cell numbers in the 
different groups were still roughly equal. 
 
Glycolysis and mitochondrial respiration are severely compromised in c-Rel 
knockout cells 
Activated T cells and cancer cells both rely on metabolic reprogramming that 
boosts processes such as glycolysis and glutaminolysis to support their growth and 
proliferation.  Thus, it is important to know which functional aspects of these 
processes are controlled by c-Rel.  We therefore performed detailed metabolic 
profiling to assess the metabolic phenotypes of the c-Rel KO Jurkat cells.  To 
measure the metabolic parameters of the control and c-Rel KO Jurkat cells, we 
quantified the oxygen consumption and lactate production of these cells using an 
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extracellular flux analyzer (Seahorse XF).  First, glycolysis was measured by lactate 
production as the extracellular acidification rate (ECAR).  Upon addition of glucose, 
c-Rel KO cells showed significantly less increase in glycolysis than the control cells.  
Next, oligomycin was added to inhibit mitochondrial ATP synthesis and achieve 
maximum glycolytic capacity.  Again, while the control cells showed a strong 
increase in ECAR, the c-Rel KO cells exhibited little change (Fig. 20).  These results 
suggest that c-Rel KO cells have a deficiency in the glycolysis pathway, resulting in a 
significantly reduced flux and limited reserve capacity that could not meet the 
metabolic demand for proliferation under nutrient stress. 
In addition to glycolysis, activated T cells and cancer cells also use TCA cycle 
and other metabolic pathways to enhance biosynthetic processes underpinning 
their growth and proliferation.  We therefore measured mitochondrial respiration of 
the c-Rel KO cells by the oxygen consumption rate (OCR).  The results revealed that 
before the electron transport chain inhibitors were added, the c-Rel KO cells showed 
significantly lower basal rate of oxygen consumption relative to the control cells.  
The addition of oligomycin suppressed oxygen consumption of both the c-Rel KO 
cells and the control cells to comparable levels, suggesting a tight coupling of oxygen 
consumption and ATP production in both groups.  After FCCP was added to 
uncouple electron transport from oxidative phosphorylation, thus allowing for 
maximal oxygen consumption, the control cells increased their oxygen consumption 
to a level significantly above the basal rate.  At the same time, c-Rel KO cells merely 
increased their oxygen consumption to the basal level (Fig. 21).  These data revealed 
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that c-Rel KO cells not only have reduced basal rates of mitochondrial respiration 
but also have significantly reduced spare respiratory capacity (SRC). 
 
c-Myc is partially responsible for the metabolic defects of c-Rel KO cells 
Having shown that c-Rel-dependent c-Myc induction is important for the 
maintenance of cell growth under nutrient stress, and that c-Rel plays a key role in 
promoting glycolysis and mitochondrial respiration, we want to find out how much 
c-Myc accounts for the metabolic function of c-Rel.  Indeed, results of the Seahorse 
assay confirmed that overexpression of c-Myc in c-Rel KO cells can rescue most of 
the mitochondrial respiration deficiency (Fig. 21).  However, it only partially 
rescued the glycolytic defect (Fig. 20).  Interestingly, qPCR quantification of the key 
glucose transporter GLUT1 revealed that c-Myc overexpression in c-Rel KO cells also 
only partially reversed the downregulation of GLUT1 in c-Rel KO cells (Fig. 22), and 
that the extent of rescue in GLUT1 expression roughly correlates with the extent of 
rescue in glycolysis. 
Collectively, these results show that c-Myc makes up a significant, but not all 
part of the c-Rel-controlled metabolic modulation 
 
c-Rel promotes glycolysis and mitochondrial respiration in primary T cells in 
mice 
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Finally, to find out whether our findings are broadly applicable to normal 
primary T cells, or only specific to the Jurkat cell line, we performed the same 
Seahorse metabolic profiling on primary CD4+ T cells isolated from WT and c-Rel KO 
mice (Fig. 23).  The results again showed that both glycolysis and mitochondrial 
respiration are severely compromised in mouse c-Rel knockout T cells. 
 
Discussion 
 Although Warburg’s findings established that most cancer cells rely primarily 
on aerobic glycolysis to generate the energy needed for their cellular activities, it 
was later recognized that they also utilize OXPHOS (Weinberg et al., 2010; Fogal et 
al., 2010).  Warburg had proposed that the aerobic glycolysis in cancer cells was 
caused by damage to the mitochondrial OXPHOS machinery.  However, later studies 
have found that the function of the OXPHOS machinery is largely intact in most 
spontaneous tumors (Lim et al., 2011; Scott et al., 2011), and that the switch from 
OXPHOS to glycolysis is often a result of active metabolic reprogramming induced 
by oncogenic mutations or environmental stress (Koppenol et al., 2011).  Relevant 
to our study, it has been shown that c-Myc plays an important role in mitochondrial 
biogenesis.  A number of nuclear-encoded regulators of mitochondrial biogenesis 
and functions are targets of c-Myc (Menssen et al., 2002; Fernandez et al., 2003).  
Our qPCR results also confirmed downregulation of two key transcription factors 
for mitochondrial biogenesis – TFAM and PPARGC1A – in c-Rel KO cells.  In fact, a 
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study using inducible c-Myc expression in human B cells showed that mitochondrial 
biogenesis is critically dependent on c-Myc expression (Li et al., 2005).  Finally, the 
c-Myc driven mitochondrial synthesis of acetyl-CoA may serve to provide a strong 
support for fatty acid biosynthesis in proliferating cells. 
In addition to c-Myc, the NF-κB family member RelA has also been shown to 
regulate cellular metabolism.  One study showed that in mouse embryo fibroblasts 
(MEFs), RelA can promote oxidative phosphorylation under glucose starvation by 
upregulating p53 expression, which in turn upregulates SCO2 – a crucial component 
of the mitochondrial cytochrome C oxidase (COX) complex that sits at the end of the 
electron transport chain (Mauro et al., 2011).  Taken together, it may not be a 
surprise that c-Rel knockout leads to defects in both glycolysis and mitochondria 
respiration. 
Having observed the impaired proliferation and reduced glucose 
consumption of the c-Rel KO cells, it is natural to question the causal relationship 
between the two phenotypes.  However, there may not be a simple answer to this 
question, as each phenotype is influenced by multiple overlapping factors and is 
subject to complex feedback regulation. Nevertheless, the results from our 
metabolic flux profiling assays may provide some important insights.  In particular, 
the data not only showed reduced glucose and oxygen consumption under standard 
conditions, but also revealed severe reductions in both total glycolytic capacity and 
spare respiratory capacity.  These results suggest that in Jurkat T cells, c-Rel is itself 
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an integral part of the metabolic machinery rather than an indirect upstream 
regulator. 
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FIGURE 19. c-Rel KO cells show reduced glucose consumption 
sgRNA control, c-Rel KO, and c-Rel KO cells transduced with c-Myc were cultured under 2% 
FBS for 2 and 7 days.  Glucose consumptions were calculated by subtracting end glucose 
concentration from the initial glucose concentration. For all panels, values represent mean ± 
SEM of pooled samples of equal numbers of cells from 3 clones (n=3; *p<0.05, **p<0.01, 
***p<0.001; one-way ANOVA). 
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FIGURE 20. c-Rel KO Jurkat cells exhibit impaired glycolysis that can be partially 
reversed by c-Myc overexpression 
The glycolytic activity and maximum glycolytic capacity were measured using a Seahorse 
extracellular flux analyzer.  A) sgRNA control Jurkat cells transduced with GFP, c-Rel KO cells 
transduced with GFP, and c-Rel KO cells transduced with c-Myc and GFP were starved under 
2% FBS for 1 day and glucose starved for 2 hours, then treated sequentially with D-glucose, 
oligomycin, and 2-Deoxyglucose (2-DG) while the extracellular acidification rates (ECAR) 
were measured in real-time.  B) Basal glycolysis is measured by the glycolytic rate defined by 
ECAR following the addition of glucose.  Maximum glycolytic capacity is represented by ECAR 
following oligomycin addition.  Values represent mean ± SEM of pooled samples of equal 
numbers of cells from 3 clones (n=6; *p<0.05, ***p<0.001; one-way ANOVA). 
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FIGURE 21. c-Rel KO Jurkat cells show compromised mitochondrial respiration that 
can be rescued by c-Myc 
sgRNA control Jurkat cells transduced with GFP, c-Rel KO cells transduced with GFP, and c-
Rel KO cells transduced with c-Myc and GFP were starved under 2% FBS for 1 day followed 
by the Seahorse mitochondrial stress test. A) Real-time recording of oxygen consumption rate 
(OCR).  B) Quantitation of the four mitochondrial parameters from the same assay.  Values 
represent mean ± SEM of pooled samples of equal numbers of cells from 3 clones (n=6; 
***p<0.001; one-way ANOVA). 
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FIGURE 22. c-Myc does not fully rescue GLUT1 deficiency in c-Rel KO cells 
sgRNA control Jurkat cells(Ctrl) transduced with GFP, c-Rel KO cells transduced with GFP, 
and c-Rel KO cells transduced with c-Myc and GFP were starved under 2% FBS for 2 days 
followed by RT-qPCR quantification of GLUT1 mRNA.  Data were normalized with GAPDH.  
Values represent mean ± SEM of pooled samples of equal amounts of RNA from 3 clones (n=3; 
***p<0.001; one-way ANOVA). 
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FIGURE 23. Primary CD4+ T cells isolated from c-Rel KO mice show significant defects 
in both mitochondrial respiration and glycolysis 
CD4+ T cells isolated from WT and c-Rel KO mice were stimulated with anti-CD3 and anti-
CD28 antibodies for up to two days followed by the Seahorse glycolysis stress (A) and 
mitochondrial stress (B) tests. Real-time recording of the extracellular acidification rates 
(ECAR) and the oxygen consumption rate (OCR) is shown in the upper and lower panel, 
respectively.  Values represent mean ± SEM of pooled samples of equal numbers of cells from 
2 mice (***p<0.001; Student’s t-test). 
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CHAPTER 4: Discussion and Future Directions 
 
Discussion: 
Results reported here indicate that c-Rel is a critical positive regulator of 
cellular metabolism.  c-Rel deficient Jurkat T cells completely lost their proliferation 
capacity under nutrient-limited conditions, thereby establishing its role as an 
indispensable stress responder.  It has previously been shown that the proliferation 
defect of c-Rel knockout mouse T cells is caused by a lack of IL-2 production upon TCR 
activation (Liou et al., 1999).  However, our data demonstrated that in humans c-Rel 
also controls intrinsic ability of these cells to survive and proliferate under nutrient 
stress independent of IL-2 signaling.  Notably, many phenotypes of the c-Rel KO Jurkat 
cells are opposite to those observed in mouse T cells deficient in Hif-1α, another 
previously-identified metabolic regulator.  Mouse T cells purified from conditional 
Hif-1α KO mice exhibit increased proliferation and cytokine production, including IL-
2 and IFN-γ (Korn et al., 2009; McNamee et al., 2013).  Whereas c-Rel KO Jurkat cells 
share many similarities with conditional c-Myc KO mouse T cells, such as 
compromised glycolysis and glutaminolysis as well as reduced cell growth and 
proliferation (Wang et al., 2011), c-Rel and c-Myc are not complete substitutes for one 
another.  For example, our data showed that glucose transporter 1 (GLUT1), a key 
regulator of glycolysis that controls glucose import, is significantly downregulated in 
the c-Rel KO cells.  However, this decrease was only partially reversed by c-Myc 
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overexpression (Fig. 22).  Yet, as demonstrated by others, ectopically expressed c-
Myc can directly induce the expression of GLUT1 (Osthus et al., 2000; Dang et al., 
2009).  Similarly, c-Myc overexpression in c-Rel KO cells almost fully rescued the 
defect in mitochondrial respiration but only partially reversed the glycolysis defect, 
which is also consistent with the incomplete rescue of GLUT1 expression. 
These findings indicate that T cell metabolism is maintained by multiple 
positive and negative regulators that could not compensate for each other; deficiency 
in any one of them leads to serious functional defects.  Our data show that c-Myc only 
accounts for a portion of c-Rel’s downstream effects, and that c-Rel also controls other 
metabolic effectors independent of c-Myc.  A number of studies have suggested that 
c-Myc can work as a global transcriptional amplifier (Nie et al., 2012; Lin et al., 2012).  
Thus, based on our results we propose the following model (Fig. 24):  Upon nutrient 
sensor-mediated activation, c-Rel activates many target genes while upregulating c-
Myc expression.  c-Myc, in turn, enhances the expression of many of these genes, i.e., 
their common targets.  In other words, c-Rel upregulates c-Myc to amplify many of its 
own targets.  Without the presence of c-Rel, c-Myc alone is insufficient to boost the 
expression of these genes to required levels, resulting in only a partial rescue.  Thus, 
c-Rel and c-Myc work in a synergistic manner to drive metabolic reprogramming and 
promote cell proliferation. 
The similar metabolic reprogramming observed during T cell activation and 
cancer transformation, i.e., the Warburg effect, and the fact that Jurkat is a human 
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acute T-cell leukemia line provides a strong implication of a mechanistic role of c-Rel 
in tumor development: By boosting glycolysis and mitochondrial respiration, c-Rel 
may provide cancer cells with the metabolic support needed to overcome the tumor-
driven nutrient deprivation in the microenvironment.  In addition to metabolic 
reprogramming, there are other ways c-Rel could contribute to cancer development.  
It has been shown in mouse that c-Rel directly controls expression of numerous 
inflammatory cytokines, such as IL-1β, IL-6, TNF-α and IFN-γ (Pahl et al., 1999), many 
of which are frequently dysregulated in autoimmune diseases and cancer.  In fact, c-
Rel-deficient mice are resistant to autoimmune diseases such as arthritis, 
experimental autoimmune encephalomyelitis, colitis, and type 1 diabetes (Campbell 
et al., 2000; Hilliard et al., 2002; Gilmore and Gerondakis, 2011).  Knowing the long-
recognized link between inflammation and cancer, it would not be surprising if c-Rel 
contributes to tumorigenesis through promotion of inflammation. 
The reliance of cancer growth on altered metabolic pathways such as aerobic 
glycolysis, glutaminolysis, and fatty acid synthesis provides the basis for attacking 
cancer cells through metabolic interference.  Targeting cancer metabolism has 
therefore become an area of intense interest and research focus.  There have been 
some promising evidence on the efficacy of this approach (Galluzzi et al., 2013; 
Bensaad et al., 2013; Zhao et al., 2013; Morales et al., 2015; Marini et al., 2016).  Given 
the critical importance of c-Rel in driving metabolic reprogramming to facilitate cell 
growth and proliferation under nutrient-deprived conditions, c-Rel could be a 
promising target for novel metabolism-based treatment strategies.  Indeed, one study 
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has shown that integrin β3-expressing human pancreatic carcinoma cells are 
resistant to EFGR tyrosine kinase inhibitor erlotinib and nutrient deprivation.  
However, this resistance can be overcome through inhibition of c-Rel using RNAi, and 
a combination of c-Rel shRNA and erlotinib successfully blocked tumor cell growth 
(Seguin et al., 2014).  Therefore, similar approaches that interfere with glycolysis 
through c-Rel inhibition represent a potentially important avenue for developing 
novel combination cancer therapies. 
 
Future directions: 
This study showed for the first time in a human system that c-Rel is a key 
metabolic regulator that promotes glycolysis and mitochondrial respiration in T cells.  
In the absence of c-Rel, Jurkat cells simply could not survive serum starvation.  It also 
showed that nutrient stress-evoked induction of c-Myc is critically dependent on c-
Rel.  Nevertheless, there are important questions remain to be answered.  First, 
although this study revealed an interesting connection between metabolic regulation 
and tumor growth under nutrient stress, the significance of this connection to the 
broader biological context in vivo remains uncertain.  Further in vivo studies will be 
needed to assess the impact of c-Rel knockout or knockdown under physiological or 
pathological conditions.  Second, since c-Myc only accounts for part of c-Rel’s 
metabolic effect, more thorough investigation are needed to identify other direct or 
indirect c-Rel targets that account for the remainder of the c-Rel-regulated metabolic 
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pathway.  Third, because cancer and activated effector T cells share many similar 
metabolic characteristics, drugs that directly targeting key metabolic regulators such 
as c-Rel will likely interfere with metabolism of both cell types.  Thus, in order to 
achieve desired targeting effect, it is crucial to understand the similarities and 
differences of metabolic pathways in cancer and in normal T cells.  Due to the 
complexity and scale of interconnection among metabolic networks, extensive 
research in these pathways remains to be done before their therapeutic potential can 
be realized. 
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FIGURE 24. Proposed mechanism for c-Rel-regulated metabolic reprogramming 
Nutrient sensors detect stress signals and activates c-Rel through the NF-κB pathway.  c-Rel 
in turn transactivates its target genes while upregulating c-Myc expression.  Enhanced c-Myc 
activity then further amplify metabolism-related genes activated by c-Rel, leading to 
increased glycolysis and glutaminolysis. 
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CHAPTER 5: Materials and Methods 
 
Cell lines 
Jurkat cells were obtained from ATCC and grown in RPMI 1640 supplemented 
with 10% or 2% fetal bovine serum (FBS, Hyclone), 2mM L-Glutamine (Gibco), and 
penicillin/streptomycin (Sigma).  
Animals 
C57BL/6 (B6) mice that carry a c-Rel gene null mutation were previously 
generated and backcrossed to B6 mice for 12 generations before used in this study 
(Hilliard et al., 2002; Liou et al., 1999).  B6 control mice were purchased from the 
Jackson Laboratory (Bar Harbor, Maine, USA).  All mice were housed in the University 
of Pennsylvania animal care facilities under pathogen-free conditions and all 
procedures were pre-approved by the institutional animal care and use committee. 
Plasmid vectors 
pCW-Cas9 and pLX-sgRNA were a gift from Eric Lander & David Sabatini 
(Addgene plasmid # 50661 & 50662).  Lentiviral vectors used for c-Rel rescue and c-
Myc overexpression were constructed based on the FUGW vector from the David 
Baltimore lab.  pGL4.12[luc2CP] luciferase reporter vector was purchased from 
Promega (Madison, Wisconsin, USA). 
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Plasmid construction 
pLX-sgRNA vectors 
sgRNA sequences were ligated to U6 promoter sequence and sgRNA scaffold 
sequence using overlap-extension PCR, followed by restriction and ligation using the 
XhoI and NheI restriction site in the pLX-sgRNA plasmid.  The sgRNA sequences used 
to generate the final c-Rel KO clones are summarized in the following table: 
sgRNA sequence Location (from 5’) Strand 
AAAACGCATTCCCCTCTGCC 52 bp Reverse 
TAGAGATAATTGAACAACCC 45 bp Forward 
TAATTGAACAACCCAGGCAG 51 bp Forward 
 
c-Rel and c-Myc rescue vectors 
The backbone vector was first create by inserting an internal ribosome entry 
site (IRES) element and the EGFP coding sequence into the FUGW vector.  Human c-
Rel and c-Myc cDNA was then cloned into the vector using the following primer sets: 
 Forward primer Reverse primer 
c-Rel ATGGCCTCCGGTGCGTATAACCCG TTATACTTGAAAAAATTCATATGGAAAG
GAG 
c-Myc CTGGATTTTTTTCGGGTAGTGGA
AAACC 
TTACGCACAAGAGTTCCGTAGCTG 
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c-Myc promoter reporter vector 
A 2kb genomic fragment containing the 5' UTR and the proximal promoter of 
the c-Myc gene were amplified by PCR from human genomic DNA, and subcloned into 
the HindIII/NcoI sites of the pGL4.12[luc2P] luciferase reporter plasmid using the 
following primer set: 
Forward primer Reverse primer 
GGCCAAGCTTAAAAGGCACGGAAGTAATA
CTCCTCTCCTC 
TCTTCCATGGTCTAAGCAGCTGCAAGG
AGAGCCTTTC 
 
Lentivirus production and cell transduction 
Lentiviruses used for generating the c-Rel KO, c-Rel KO c-Rel rescue, c-Rel KO 
c-Myc rescue, and the control cells were produced by co-transfecting the respective 
vectors with  the 3rd generation packaging system into 80% confluent 293T cells 
using the FuGENE 6 (Promega, Madison, WI) transfection reagent according to the 
manufacturer's instructions.  Virus-containing supernatants were collected and 
filtered 36-48 h after transfection, and were either used immediately or stored at -
80°C. 
Jurkat cells were transduced in viral supernatants containing 10µg/mL 
polybrene at a density of 2x105 cells/mL, and were centrifuged under 3000 rpm, 30°C 
for 90 min, followed by replacement of fresh culture medium. 
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Generation of c-Rel KO cells using the CRISPR/Cas9 system (Fig. 25) 
 c-Rel KO Jurket cells were generated using the CRISPR/Cas9 system described 
by Wang et al. Specifically, 8 candidate sgRNA target sequences were generated based 
on complementarity to the N-terminus region of the c-Rel coding sequence.  These 
target sequences were then fused to the sgRNA scaffold sequence and cloned into the 
pLX-sgRNA vector using the XhoI and NheI restriction sites.  The resulting vectors 
were used to produce lentiviruses in 293T cells by co-transfection with the 3rd 
generation packaging system.  Jurkat cells were first transduced by lentivirus 
produced from the doxycycline-inducible Cas9 vector (pCW-Cas9) and selected under 
1.5µg/mL puromycin for 3 days.  The resulting cells were expanded and transduced 
by the c-Rel-targeting pLX-sgRNA lentiviruses and subsequently selected under 
6µg/mL blasticidin in the presence of 750ng/mL doxycycline for one week.  The cells 
were then expanded without doxycycline until sufficient number is obtained.  c-Rel 
protein levels were then analyzed by western blotting. 
Clonal selection to establish pure c-Rel KO lines 
 Jurkat cells were serial diluted to 0.5 cells / 200µL / well in 96-well plates and 
grew until density reaches confluency.  The cells were then transferred to 12-well 
plates and expanded until sufficient number is obtained.  c-Rel protein levels were 
then analyzed by western blotting. 
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PMA/Ionomycin stimulation of Jurkat cells 
1x106/mL Jurkat cells were stimulated in standard culture medium containing 
10% FBS with the addition of 10ng/mL PMA and 1µM ionomycin for 4 hours before 
analyzed. 
Mouse T cell isolation and stimulation 
CD4+ T cells were isolated from spleens of 8-12 week old, age-matched male 
and female c-Rel KO and B6 mice using surface antigen and magnetic beads-based 
negative selection kit (mouse CD4+ T Cell Isolation Kit, Miltenyi Biotec) according to 
the manufacturer's instructions. After isolation, the WT or c-Rel KO cells were 
expanded with a 1:3 (cell:bead) ratio with mouse anti-CD3/CD28 beads for 2 days. 
Western blotting 
Cells were lysed in SDS and total protein concentration determined. 30µg 
protein was loaded to each lane, and separated by SDS-PAGE. After transferring to a 
nitrocellulose membrane, it was blocked with 5% milk in TBST and probed with the 
following primary antibodies, overnight at 4°C: c-Rel (#4727, rabbit polyclonal, 
1:2000, Cell signaling), c-Myc (#9402, rabbit monoclonal, 1:1000, Cell Signaling), β-
Actin (1:10000, mouse monoclonal, Sigma). HRP-conjugated secondary antibodies 
(anti-mouse or anti-rabbit IgG, 1:1000, GE healthcare) were incubated at room 
temperature for 2 hours. Detection was done using Amersham enhanced 
chemiluminescence (ECL). 
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Cell sorting by flow cytometry 
Flow cytometric sorting was performed on Jurkat cells transduced with 
vectors carrying a GFP marker.  Cells were analyzed on a BD FACS Aria II sorter. Data 
were analyzed with the FlowJo software. 
Quantitative RT-PCR 
Total RNA was extracted with RNEasy (Qiagen, Valencia, CA) according to the 
manufacturer's instructions. Reverse transcription was performed with oligo dT 
primers. Real-time PCR was carried out in an Applied Biosystems 7500 system with 
Power SYBR Green PCR Master Mix (Applied Biosystems). Relative levels of gene 
expression were determined with GAPDH as the control.  The primers used in the 
experiments are summarized in Table 1. 
Gene Forward primer Reverse primer 
GAPDH GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG 
IL-2 GTCACAAACAGTGCACCTAC CCCTGGGTCTTAAGTGAAAG 
c-Rel GCAGGAATCAATCCATTCAA CAGGAGGAAGAGCAGTCGTC 
c-Myc TTCGGGTAGTGGAAAACCAG AGTAGAAATACGGCTGCACC 
SLC2A1 AAAGTGACAAGACACCCGAG TGTCAGGTTTGGAAGTCTCATC 
NR4A2 TCCTCGAAAACGCCTGTAAC TGGAGTTAAGAAATCGGAGCTG 
NR4A3 AGTGTCTCAGTGTTGGAATGG AGGAGAAGGTGGAGAGGG 
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SLC27A2 CGAGAAAAGTTGGTGCTGTTG TGGGAACTCTGACGCAATATC 
PPARGC1A ACCAAACCCACAGAGAACAG GGTCAGAGGAAGAGATAAAGTTG 
TFAM GATTGAAGTTGGACGAAAGGATC CGATAGCTTCAGGTATTGAGACC 
 
Luciferase reporter assay 
Control and c-Rel KO Jurkat cells were transfected with either promoterless 
control plasmid or pGL4.12[luc2CP] c-Myc reporter plasmid by electroporation using 
a Gene Pulser II electroporator (Bio-Rad) at a concentration of 20µg/5x106 cells/mL.  
Cells were rested for 4 hours and stimulated with 10ng/ml PMA and 1µM ionomycin.  
12 hours after stimulation, cells were lysed, and luciferase activities were measured 
using a luciferase assay kit (Promega) and a GloMax 20/20 luminometer (Promega), 
according to the manufacturer's protocols.  
Seahorse metabolic analysis 
For Jurkat cells, cells were moved to RPMI 1640 medium containing 2% FBS 
for 1 day before seeded to 96-well format plates.  For mouse primary T cells, cells 
were expanded with a 1:3 (cell:bead) ratio with mouse anti-CD3/CD28 beads for up 
to 2 days before seeding.  Cells were harvested and resuspended at 5x106 cells/mL in 
appropriate Seahorse media. 40µL of cells were added to 140µL of appropriate 
seahorse media and plated in XF96 cell culture microplates that were precoated with 
68 
 
25µL of Cell tak reagent overnight according to manufacturer’s instructions (Corning, 
354240). 
For examining glycolysis, the Seahorse glyo-stress test kit was used with 
additions of the following reagents to cells in glucose-free Seahorse media: 10mM 
glucose, 1µM oligomycin and 50mM 2-DG. To determine the rate of glycolysis, cells 
were incubated in glucose-free medium and the increased ECAR response upon 
stimulation of glycolysis by glucose and oligomycin was determined. Oligomycin 
inhibits mitochondrial ATP synthase (complex V) forcing glycolysis to compensate for 
the lack of ATP production in oxidative phosphorylation. Finally, 2-Dexoglucose 
(2DG) was added to inhibit glycolysis. Glycolysis was calculated as the difference 
between the ECAR after addition of glucose and the baseline ECAR. Glycolytic capacity 
was calculated as the difference between the ECAR after addition of oligomycin and 
the baseline ECAR. 
For examining mitochondrial function, a mito-stress kit was used with 
additions of the following reagents to cells in appropriate Seahorse media: 1µM 
Oligomycin, 1µM fluoro-carbonyl cyanide phenylhydrazone (FCCP, an uncoupler of 
respiration and oxidative ATP synthesis), and pre-mixed 0.5 µM rotenone + antimycin 
A solution (Electron Transport Chain complex I and III inhibitors). Maximum 
respiratory capacity was calculated as the difference between the Oxygen 
Consumption Rate (OCR) after addition of FCCP and the OCR after addition of 
rotenone/antimycin A. Spare respiratory capacity was calculated as the difference 
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between maximal (post FCCP) and basal respiration. Plates were run on a Seahorse 
XF96 Extracellular Flux Analyzer according to the manufacturer's protocols. 
Statistical analyses 
All statistics were performed using Prism 5 (GraphPad, La Jolla, CA).  Data 
were expressed as mean ± standard error of mean (SEM) throughout the manuscript.  
For comparisons between two groups, two-tailed Student's t-test was used for 
evaluation of statistical significance.  For comparisons across multiple groups, one-
way ANOVA with Bonferroni post-test adjustment was used.  Data shown are 
representative of two to three independent experiments.  NS, not significant; *, 
p<0.05; **, p<0.01; ***, p<0.001. 
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FIGURE 25. Process of generating c-Rel knockout Jurkat cells and control cells 
A) Jurkat cells were first transduced by tet-on Cas9-expressing lentiviral vector carrying a 
puromycin selection marker and treated with puromycin for 2 weeks.  Selected cells were 
then transduced with a sgRNA-expression lentiviral vector carrying a blasticidin selection 
marker and treated with blasticidin and doxycycline for 2 weeks.  The resulting cells were 
analyzed by western blotting.  sgRNA groups showing strong c-Rel knockdown were 
continued with clonal selection to produce pure knockout lines. 
B) sgRNA control cell underwent the same processes as the c-Rel KO cells, except with a 
different sgRNA.  Control groups used to asses rescuing effect of c-Rel and c-Myc 
overexpression underwent the same number of transductions and selections, except with a 
GFP only lentiviral vector. 
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